Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.

Polaprezinc noninferior to rebamipide as add-on to PPI for treating ulcer following ESD

17 May 2020

In patients with endoscopic submucosal dissection (ESD)-induced ulcer, the combination of polaprezinc plus proton pump inhibitor (PPI) promotes healing as effectively as rebamipide plus PPI, as shown in a study.

Although widely used to treat gastric neoplasms, ESD causes large and deep artificial ulcers, researchers said, adding that there are no guidelines with regard to the optimal treatment durations and drug regimens for ESD-induced ulcers.

A total of 210 patients who had developed ulcer following ESD were randomized to receive treatment with either polaprezinc (150 mg/d) or rebamipide (300 mg/d) in addition to pantoprazole (40 mg/d). Researchers used χ2 or Fisher exact test and the Student t test to evaluate ulcer healing rate and its condition at 4 weeks after dissection.

Polaprezinc showed noninferiority to rebamipide in terms of ulcer healing rate 4 weeks following ESD both in the intention-to-treat analysis (90.3 percent vs 91.4 percent, respectively; p=0.523) and per-protocol analysis (89.9 percent vs 91.1 percent, respectively; p=0.531).

A short procedure time independently predicted a high ulcer healing rate (odds ratio, 0.975, 95 percent confidence interval, 0.958–0.993; p=0.006).

Polaprezinc is an antiulcer agent that inhibits proinflammatory cytokine-induced NF-κB activation and interleukin-8 expression in gastric epithelial cells, promoting ulcer healing. The drug is commonly prescribed for gastric ulcers in Japan. [Biol Trace Elem Res 2014;158:280-288]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 18 Sep 2020
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.